Advances in Inflammatory Bowel Disease

Dear Colleagues,

In the last few decades, spectacular progress has been made in understanding the pathogenesis of inflammatory bowel disease (IBD) as well as its management. On the other hand, we still face many challenges, such as caring for IBD patients in the COVID-19 pandemic, oncologic surveillance, the safety of modern therapy and many others. In the pandemic, many concerns have been raised, including those regarding specialistic care and treatment availability. New management guidelines for the COVID-19 era have been issued. IBD treatment is not standard and needs a targeted and personalized approach, based on specific determinants. Those may enable understanding the different IBD phenotypes. The disease affects the lives of the patients in many aspects, so we need to improve our understanding of patients’ perspectives and preferences for its management. The evaluation of health-related quality of life may be considered in everyday practice. The distinct pathogenesis, clinical course and management of IBD in children and adults should be emphasized. Many new biological compounds raise questions about their safety, particularly regarding neoplasia, both in monotherapy as well as in combination with other drugs. There are still many gaps in our knowledge of IBD’s pathogenesis and the mechanisms of inflammation and fibrosis as well as the role of adipokines and other cytokines, which should be addressed. Other important issue is the need to seek a more uniform approach to this difficult group of patients in different countries.

Prof. Dr. Ewa Małecka-Panas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.